Chronic graft-versus-host disease and the risk of primary disease relapse: A meta-analysis
•Both PDR and cGVHD have long been the dreaded outcomes for patients with hematologic malignancies.•We conducted a random effect meta-analysis of 11 studies involving 64,239 participants and found a significant decreased risk of developing PDR in patients with cGVHD, with a pooled risk ratio of 0.49...
Gespeichert in:
| Veröffentlicht in: | Experimental hematology 2019-06, Vol.74, p.33-41 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 41 |
|---|---|
| container_issue | |
| container_start_page | 33 |
| container_title | Experimental hematology |
| container_volume | 74 |
| creator | Poonsombudlert, Kittika Kewcharoen, Jakarin Kanitsoraphan, Chanavuth Prueksapraopong, Chattip Limpruttidham, Nath |
| description | •Both PDR and cGVHD have long been the dreaded outcomes for patients with hematologic malignancies.•We conducted a random effect meta-analysis of 11 studies involving 64,239 participants and found a significant decreased risk of developing PDR in patients with cGVHD, with a pooled risk ratio of 0.49 (95% CI: 0.40–0.61, I2 = 69.3%).•We concluded that patients with cGVHD have a significantly lower risk of developing PDR compared with patients without cGVHD.•According to regression meta-analysis, use of ATG and HLA mismatch grafts had a potential modifying effect on the association between cGVHD and PDR.
Both primary disease relapse (PDR) and chronic graft-versus-host disease (cGVHD) have long been the dreaded outcomes for patients with hematologic malignancies. Previous theories have speculated an inverse relationship between the two; therefore, we attempted to verify the described association. We searched for titles of articles in MEDLINE (PubMed), Cochrane library, and EMBASE database that evaluated the association between PDR and cGVHD and conducted a random effect meta-analysis of 11 studies involving a total of 64,239 participants. We found a significantly decreased risk of developing PDR in patients with cGVHD, with a pooled risk ratio of 0.49 (95% confidence interval: 0.40–0.61, I2 = 69.3%). We concluded that patients with cGVHD have a significantly lower risk of developing PDR compared with patients without cGVHD. |
| doi_str_mv | 10.1016/j.exphem.2019.04.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2229245082</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0301472X19301882</els_id><sourcerecordid>2229245082</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-6aba7c5dd069870dd3e6113f7a58c56d52bfadb9c8c29b4b3d6a5718df4e368a3</originalsourceid><addsrcrecordid>eNp9kMtqHDEQRUWIyYyd_EEwWmbT7dKjH8rCMAzxAwzZ2GCyEWqpOqNxP8aqHhP_fdrMxMusalHn1qUOY18F5AJEebHN8c9ug30uQZgcdA6gP7ClqCuVSWXMR7YEBSLTlXxcsFOiLQAUhYFPbKEE6MqUasl-rTdpHKLnv5Nrp-wFE-0p24w08RAJHSF3Q-DTBnmK9MTHlu9S7F16fd8n7NyO8Dtf8R4nl7nBda8U6TM7aV1H-OU4z9jD1Y_79U129_P6dr26y7yGespK17jKFyFAaeoKQlBYCqHayhW1L8pQyKZ1oTG-9tI0ulGhdEUl6tBqVGXt1Bn7dri7S-PzHmmyfSSPXecGHPdkpZRG6gJqOaP6gPo0EiVs7fEZK8C-WbVbe7Bq36xa0Ha2OsfOjw37psfwHvqncQYuDwDOf75ETJZ8xMFjiAn9ZMMY_9_wFxKOi50</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2229245082</pqid></control><display><type>article</type><title>Chronic graft-versus-host disease and the risk of primary disease relapse: A meta-analysis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Poonsombudlert, Kittika ; Kewcharoen, Jakarin ; Kanitsoraphan, Chanavuth ; Prueksapraopong, Chattip ; Limpruttidham, Nath</creator><creatorcontrib>Poonsombudlert, Kittika ; Kewcharoen, Jakarin ; Kanitsoraphan, Chanavuth ; Prueksapraopong, Chattip ; Limpruttidham, Nath</creatorcontrib><description>•Both PDR and cGVHD have long been the dreaded outcomes for patients with hematologic malignancies.•We conducted a random effect meta-analysis of 11 studies involving 64,239 participants and found a significant decreased risk of developing PDR in patients with cGVHD, with a pooled risk ratio of 0.49 (95% CI: 0.40–0.61, I2 = 69.3%).•We concluded that patients with cGVHD have a significantly lower risk of developing PDR compared with patients without cGVHD.•According to regression meta-analysis, use of ATG and HLA mismatch grafts had a potential modifying effect on the association between cGVHD and PDR.
Both primary disease relapse (PDR) and chronic graft-versus-host disease (cGVHD) have long been the dreaded outcomes for patients with hematologic malignancies. Previous theories have speculated an inverse relationship between the two; therefore, we attempted to verify the described association. We searched for titles of articles in MEDLINE (PubMed), Cochrane library, and EMBASE database that evaluated the association between PDR and cGVHD and conducted a random effect meta-analysis of 11 studies involving a total of 64,239 participants. We found a significantly decreased risk of developing PDR in patients with cGVHD, with a pooled risk ratio of 0.49 (95% confidence interval: 0.40–0.61, I2 = 69.3%). We concluded that patients with cGVHD have a significantly lower risk of developing PDR compared with patients without cGVHD.</description><identifier>ISSN: 0301-472X</identifier><identifier>EISSN: 1873-2399</identifier><identifier>DOI: 10.1016/j.exphem.2019.04.004</identifier><identifier>PMID: 31047963</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Chronic Disease ; Female ; Graft vs Host Disease - epidemiology ; Graft vs Host Disease - etiology ; Hematologic Neoplasms - epidemiology ; Hematologic Neoplasms - therapy ; Humans ; Male ; Recurrence ; Risk Factors</subject><ispartof>Experimental hematology, 2019-06, Vol.74, p.33-41</ispartof><rights>2019 ISEH -- Society for Hematology and Stem Cells</rights><rights>Copyright © 2019 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-6aba7c5dd069870dd3e6113f7a58c56d52bfadb9c8c29b4b3d6a5718df4e368a3</citedby><cites>FETCH-LOGICAL-c408t-6aba7c5dd069870dd3e6113f7a58c56d52bfadb9c8c29b4b3d6a5718df4e368a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0301472X19301882$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31047963$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Poonsombudlert, Kittika</creatorcontrib><creatorcontrib>Kewcharoen, Jakarin</creatorcontrib><creatorcontrib>Kanitsoraphan, Chanavuth</creatorcontrib><creatorcontrib>Prueksapraopong, Chattip</creatorcontrib><creatorcontrib>Limpruttidham, Nath</creatorcontrib><title>Chronic graft-versus-host disease and the risk of primary disease relapse: A meta-analysis</title><title>Experimental hematology</title><addtitle>Exp Hematol</addtitle><description>•Both PDR and cGVHD have long been the dreaded outcomes for patients with hematologic malignancies.•We conducted a random effect meta-analysis of 11 studies involving 64,239 participants and found a significant decreased risk of developing PDR in patients with cGVHD, with a pooled risk ratio of 0.49 (95% CI: 0.40–0.61, I2 = 69.3%).•We concluded that patients with cGVHD have a significantly lower risk of developing PDR compared with patients without cGVHD.•According to regression meta-analysis, use of ATG and HLA mismatch grafts had a potential modifying effect on the association between cGVHD and PDR.
Both primary disease relapse (PDR) and chronic graft-versus-host disease (cGVHD) have long been the dreaded outcomes for patients with hematologic malignancies. Previous theories have speculated an inverse relationship between the two; therefore, we attempted to verify the described association. We searched for titles of articles in MEDLINE (PubMed), Cochrane library, and EMBASE database that evaluated the association between PDR and cGVHD and conducted a random effect meta-analysis of 11 studies involving a total of 64,239 participants. We found a significantly decreased risk of developing PDR in patients with cGVHD, with a pooled risk ratio of 0.49 (95% confidence interval: 0.40–0.61, I2 = 69.3%). We concluded that patients with cGVHD have a significantly lower risk of developing PDR compared with patients without cGVHD.</description><subject>Chronic Disease</subject><subject>Female</subject><subject>Graft vs Host Disease - epidemiology</subject><subject>Graft vs Host Disease - etiology</subject><subject>Hematologic Neoplasms - epidemiology</subject><subject>Hematologic Neoplasms - therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Recurrence</subject><subject>Risk Factors</subject><issn>0301-472X</issn><issn>1873-2399</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtqHDEQRUWIyYyd_EEwWmbT7dKjH8rCMAzxAwzZ2GCyEWqpOqNxP8aqHhP_fdrMxMusalHn1qUOY18F5AJEebHN8c9ug30uQZgcdA6gP7ClqCuVSWXMR7YEBSLTlXxcsFOiLQAUhYFPbKEE6MqUasl-rTdpHKLnv5Nrp-wFE-0p24w08RAJHSF3Q-DTBnmK9MTHlu9S7F16fd8n7NyO8Dtf8R4nl7nBda8U6TM7aV1H-OU4z9jD1Y_79U129_P6dr26y7yGespK17jKFyFAaeoKQlBYCqHayhW1L8pQyKZ1oTG-9tI0ulGhdEUl6tBqVGXt1Bn7dri7S-PzHmmyfSSPXecGHPdkpZRG6gJqOaP6gPo0EiVs7fEZK8C-WbVbe7Bq36xa0Ha2OsfOjw37psfwHvqncQYuDwDOf75ETJZ8xMFjiAn9ZMMY_9_wFxKOi50</recordid><startdate>201906</startdate><enddate>201906</enddate><creator>Poonsombudlert, Kittika</creator><creator>Kewcharoen, Jakarin</creator><creator>Kanitsoraphan, Chanavuth</creator><creator>Prueksapraopong, Chattip</creator><creator>Limpruttidham, Nath</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201906</creationdate><title>Chronic graft-versus-host disease and the risk of primary disease relapse: A meta-analysis</title><author>Poonsombudlert, Kittika ; Kewcharoen, Jakarin ; Kanitsoraphan, Chanavuth ; Prueksapraopong, Chattip ; Limpruttidham, Nath</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-6aba7c5dd069870dd3e6113f7a58c56d52bfadb9c8c29b4b3d6a5718df4e368a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Chronic Disease</topic><topic>Female</topic><topic>Graft vs Host Disease - epidemiology</topic><topic>Graft vs Host Disease - etiology</topic><topic>Hematologic Neoplasms - epidemiology</topic><topic>Hematologic Neoplasms - therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Recurrence</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Poonsombudlert, Kittika</creatorcontrib><creatorcontrib>Kewcharoen, Jakarin</creatorcontrib><creatorcontrib>Kanitsoraphan, Chanavuth</creatorcontrib><creatorcontrib>Prueksapraopong, Chattip</creatorcontrib><creatorcontrib>Limpruttidham, Nath</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Experimental hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Poonsombudlert, Kittika</au><au>Kewcharoen, Jakarin</au><au>Kanitsoraphan, Chanavuth</au><au>Prueksapraopong, Chattip</au><au>Limpruttidham, Nath</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic graft-versus-host disease and the risk of primary disease relapse: A meta-analysis</atitle><jtitle>Experimental hematology</jtitle><addtitle>Exp Hematol</addtitle><date>2019-06</date><risdate>2019</risdate><volume>74</volume><spage>33</spage><epage>41</epage><pages>33-41</pages><issn>0301-472X</issn><eissn>1873-2399</eissn><abstract>•Both PDR and cGVHD have long been the dreaded outcomes for patients with hematologic malignancies.•We conducted a random effect meta-analysis of 11 studies involving 64,239 participants and found a significant decreased risk of developing PDR in patients with cGVHD, with a pooled risk ratio of 0.49 (95% CI: 0.40–0.61, I2 = 69.3%).•We concluded that patients with cGVHD have a significantly lower risk of developing PDR compared with patients without cGVHD.•According to regression meta-analysis, use of ATG and HLA mismatch grafts had a potential modifying effect on the association between cGVHD and PDR.
Both primary disease relapse (PDR) and chronic graft-versus-host disease (cGVHD) have long been the dreaded outcomes for patients with hematologic malignancies. Previous theories have speculated an inverse relationship between the two; therefore, we attempted to verify the described association. We searched for titles of articles in MEDLINE (PubMed), Cochrane library, and EMBASE database that evaluated the association between PDR and cGVHD and conducted a random effect meta-analysis of 11 studies involving a total of 64,239 participants. We found a significantly decreased risk of developing PDR in patients with cGVHD, with a pooled risk ratio of 0.49 (95% confidence interval: 0.40–0.61, I2 = 69.3%). We concluded that patients with cGVHD have a significantly lower risk of developing PDR compared with patients without cGVHD.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>31047963</pmid><doi>10.1016/j.exphem.2019.04.004</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-472X |
| ispartof | Experimental hematology, 2019-06, Vol.74, p.33-41 |
| issn | 0301-472X 1873-2399 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2229245082 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Chronic Disease Female Graft vs Host Disease - epidemiology Graft vs Host Disease - etiology Hematologic Neoplasms - epidemiology Hematologic Neoplasms - therapy Humans Male Recurrence Risk Factors |
| title | Chronic graft-versus-host disease and the risk of primary disease relapse: A meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T07%3A06%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20graft-versus-host%20disease%20and%20the%20risk%20of%20primary%20disease%20relapse:%20A%20meta-analysis&rft.jtitle=Experimental%20hematology&rft.au=Poonsombudlert,%20Kittika&rft.date=2019-06&rft.volume=74&rft.spage=33&rft.epage=41&rft.pages=33-41&rft.issn=0301-472X&rft.eissn=1873-2399&rft_id=info:doi/10.1016/j.exphem.2019.04.004&rft_dat=%3Cproquest_cross%3E2229245082%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2229245082&rft_id=info:pmid/31047963&rft_els_id=S0301472X19301882&rfr_iscdi=true |